Chronic disease proteome program (CDPP)
„A unique approach combining proteomics and artificial intelligence to enable personalized medicine - reducing organ-damages and loss of life years!"
Who, what, why?
Chronic diseases - the scourge of humanity *
- Chronic diseases lead to permanent restrictions in quality of life and a reduction in life expectancy by up to 20 years!
- Chronic kidney disease increases the risk of cardiovascular disease by up to 20 times.
* UN-Resolution adopted by the General Assembly, 64/265. "Prevention and control of non-communicable diseases", 2011.
They are detected far too late - only when significant organ damage has occurred!
Now: epochal improvement through proteomic analysis
All chronic diseases have in common the pre-damage caused by fibrosis and endothelial damage. Even this early damage is now detected for the first time by proteomic analysis based on collagen proteins in the filtrate of the blood and urine.
Proteomic analysis in combination with artificial intelligence enables the decoding and early detection of chronic diseases
Early detection of chronic kidney disease, heart failure and coronary heart disease using proteomic analysis alone can reduce the risk of mortality by 30%.
- Diseases arise at the molecular and cellular level, with proteins being the main regulators.
- Drugs usually only work at the protein level and are most effective when used at an early stage of the disease.
Once the cells and organs are irreparably damaged, the progressive loss of organ function can no longer be stopped, but at best can be slowed down. That is the current situation.
The non-invasive proteomic tests detect chronic diseases early on at the molecular and cellular level. The self-learning algorithms, which consist of a combination of disease-specific protein biomarkers and artificial intelligence, have been validated in over 100 clinical studies. The benefits of the tests offered, including for cancer, chronic kidney and cardiovascular diseases, have been described in detail in over 400 scientific publications.
The tests were funded by the EU Commission (among others SYSKID, EU MASCARA, HOMAGE, DC-ren, PRIORITY). The in-vitro diagnostic (IVD) tests are registered and approved in the EU.
Urine proteome test
The proteome test is very precise and can provide reliable information about the development of chronic diseases at a very early stage because it is the first time that the proteome has been decoded and taken from a single sample. All molecular - cellular - disease-specific changes are controlled exclusively by proteins. The primary source of proteome analysis is, among many other body fluids, urine! It is the "filtrate of the blood", extremely stable, for example, compared to blood, which loses a lot of important proteomic information even when frozen at -80° Celsius.
The kidneys are a very delicate organ with around 1.7 million filter units (nephrons) per kidney. Every day (24 hours) they filter around 1,700 liters of fluid, essentially "blood," and pass on all the proteomic information that has caused the disease-specific changes. The analyzed urine contains up to a million data points and up to 12,000 proteins/peptides. If other body fluids are also present at the site of the disease to be diagnosed, e.g. in the case of bile duct cancer, bile secretion can also be analyzed, which combined achieves an accuracy of better than 95%.
For more information about mosaiques clinical proteomics, please visit:
Application and consequences of urine proteomic tests in patients at risk for chronic diseases
In case of a positive test result, treatment including management of risk factors according to guidelines is initiated to prevent the onset or progression of chronic disease. In case of negative results of urine proteomic tests, follow-up should be performed in 2-3 years.
The unique proteome analysis enables very early and very accurate diagnostics for the first time - here are the study results:
